Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog

Abstract

BackgroundWe investigated the efficiency, safety and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog.MethodsWe initially enrolled 44 eyes from 44 primary open angle glaucoma patients, and a total of 42 patients completed the study. All patients were under treatment with various prostaglandin F2α analogs and dorzolamide 1%/timolol 0.5%. While maintaining the prostaglandin F2α analog, dorzolamide 1%/timolol 0.5% was switched to brinzolamide 1%/timolol 0.5%. Conjunctival hyperemia, superficial punctate keratopathy, and intraocular pressure (IOP) were evaluated at baseline and at 4, 12, and 24 weeks. Adverse events and patient preferences, measured using a questionnaire at study initiation and at 24 weeks, were also noted.ResultsThe IOP was 17.7±1.7, 16.8±2.6, 16.7±2.2, and 16.7±2.4 mmHg at baseline and at 4, 12, and 24 weeks, respectively, with no significant differences in IOP values at any time point (P=0.117, one-way analysis of variance). In addition, no significant differences were found in the incidence of conjunctival hyperemia or SPK score at any time point (all P>0.5, by Kruskal–Wallis test). Based on the evaluation of side effects using the questionnaire, stinging/burning was less common (P=0.042), while blurred vision was more common (P=0.003), after switching to brinzolamide 1%/timolol 0.5%. Regarding patient preferences, 13 patients (31%) preferred dorzolamide 1%/timolol 0.5%, 12 patients (29%) preferred brinzolamide 1%/timolol 0.5%, and 17 patients (40%) preferred neither.ConclusionWhen switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5%, the IOP values and incidence of superficial punctate keratopathy and conjunctival hyperemia were sustained throughout the 24-week observation period, and the patient preferences were similar for the two regimens. However, differences were observed in the ocular sensations of stinging/burning with dorzolamide 1%/timolol 0.5% and blurred vision with brinzolamide 1%/timolol 0.5%.

Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin‐treated glaucoma patients

“…2015; Shimizu et al. 2015). However, these data may be compromised by the impact of treatment adherence before and after switching regimens and by IOP fluctuations with the timing of eyedrop administration.…”

“…Moreover, in a Japanese study, Shimizu et al. (2015) compared the usability of drugs after switching from DTFC to BTFC and showed increased incidence of blurred vision in those switching to BTFC, but reduced ocular irritation and burning sensation.…”

Comparison of Efficacy and Safety of Topical Dorzolamide-Timolol Maleate Combination with Oral Acetazolamide for Prevention of Intraocular Pressure Rise Following Phacoemulsification Surgery

“…R Re es su ul lt ts s: : The mean preoperative intraocular pressure (IOP) of the first group was 14.60±3.21 standard deviation (SD) (range 10-21) mmHg. and that of the second group was 14.67±2.77 (SD) (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) mmHg (p=0.924). The mean postoperative IOP(1 st day) of the first group was 15.27±2.90 (SD) (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) mmHg and that of the second group was 14.82±2.57 (SD) (11-23) mmHg (p=0.505).…”

“…and that of the second group was 14.67±2.77 (SD) (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) mmHg (p=0.924). The mean postoperative IOP(1 st day) of the first group was 15.27±2.90 (SD) (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) mmHg and that of the second group was 14.82±2.57 (SD) (11-23) mmHg (p=0.505). The mean postoperative IOP (1 st week) of the first group was 13.72±2.44 (SD) (10-18) mmHg and that of the second group was 13.64±2.53 (SD) (10)(11)(12)(13)(14)(15)(16)(17)(18)(19) mmHg (p=0.895).…”

“…The mean postoperative IOP(1 st day) of the first group was 15.27±2.90 (SD) (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) mmHg and that of the second group was 14.82±2.57 (SD) (11-23) mmHg (p=0.505). The mean postoperative IOP (1 st week) of the first group was 13.72±2.44 (SD) (10-18) mmHg and that of the second group was 13.64±2.53 (SD) (10)(11)(12)(13)(14)(15)(16)(17)(18)(19) mmHg (p=0.895). C Co on nc cl lu us si io on n: : For prophylaxis of postoperative IOP rise after an uneventful cataract surgery, topical-dorzolamid timolol maleate combination and oral acetazolamide therapy have similar effects, however the adverse effects of systemic acetazolamide should be taken into account.…”